Now showing items 1-5 of 5
Occult breast carcinoma in breast reduction specimens in European women.
Breast reduction is a common surgical procedure performed by plastic and oncoplastic breast surgeons. The authors report on the incidence and management of cancer and atypical hyperplasia in breast reduction specimens from ...
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while ...
Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT.
BACKGROUND: Over 44,000 women are diagnosed with breast cancer annually in the UK. The research comprised three workstreams (WSs) focused on older women. MAXIMISING SURVIVAL: WS1 – to identify the role of older women’s and ...
Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
Family history of breast cancer is a key risk factor, accounting for up to 10% of cancers. We evaluated the proactive assessment of familial breast cancer (FBC) risk in primary care. Eligible women (30 to 60 years) were ...
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ breast cancer. ...